Drugs / Quadrivalent influenza vaccine(Split Virion),Inactivated
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05779020 | Apr 2023 → Sep 2024 | influenza | Butantan Institute | Completed | No outcome recorded |
| Phase 3 | NCT05642078 | Feb 2023 → Jan 2024 | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT05512494 | Nov 2022 → Jan 2023 | influenza | Sinovac Biotech Co., Ltd | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Influenza Vaccine (Split Virion), inactivated | “Quadrivalent influenza vaccine(Split Virion),Inactivated，Produced by Anhui Zhifei Longcom Biopharmceutical Co., Ltd.；0.25mL/branch, each contains 7.5 μg H1N1, H3N2, B(V), B(Y)...” NCT05642078 ↗ |
| Known as | QIV-IB | “The study interventions are the Butantan Quadrivalent Influenza Vaccine (split virion, inactivated) in two dose scheme (QIV-IB/0.25ml and QIV-IB/0.50ml) and the active controls...” NCT05779020 ↗ |
| Modality | Vaccine | “Quadrivalent influenza vaccine(Split Virion),Inactivated” NCT05642078 ↗ |
| Route | Intramuscular | “The routine of administration is intramuscular injection into deltoid region.” NCT05512494 ↗ |